CClinicalTrials.gg
CompletedNCT03562312PACEUpdated Apr 15, 2020

Performance Anxiety Changes With Exercise

An interventional study of high-intensive aerobe exercise and low-intensive aerobe exercise in Performance Anxiety, sponsored by Charite University, Berlin, Germany. Completed at 1 site in Germany. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-04-15.

Sponsored by Charite University, Berlin, Germany · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study investigates the effect of high-intense aerobe exercise training (HIIT) and aerobe exercise of low intensity on clinical and physiological parameters (anxiety, activity, cortisol, alpha amylase, heart rate, heart rate variability, spiroergometry) in patients with Music Performance Anxiety (MPA). Half of the patients will receive HIIT, while the other half will receive aerobe exercise of low intensity.

Read the detailed description

In this study, 20 patients with MPA will receive a high-intensive aerobe training (HIIT, 6 HIIT-sessions of 20 minutes within a period of 12 days). Additionally, 20 MPA-patients will undergo a less intense aerobe training matched regarding frequency and duration of sessions. Prior to the first training session, after completing the training (day 12) and 10 days after the Training (day 22), symptoms of anxiety and will be assessed by using questionnaires. Moreover, heart rate and heart rate variability will be obtained and activity level is measured using accelerometers. Before and after the training there will be an assessment of saliva samples for measuring cortisol and alpha amylase.

Furthermore, a standardized performance situation is established before and after the Training. Before, during and after the performance anxiety ratings, cortisol, alpha amylase, heart rate and heart rate variability are assessed.

The investigators hypothesize, that patients with MPA which undergo HIIT, will show a stronger and more sustained improvement of both, clinical symptoms and physiological measures. Specifically, a decreased heart rate, higher heart rate variability and decreased endocrinological parameters.

02

Conditions studied

  • Performance Anxiety

Browse trials for

Keywords

  • MPA
  • Music Performance Anxiety
  • HIIT
  • Exercise
  • Cortisol
  • HRV
  • Heart Rate
03

In context

Anxiety Disorders

4,868 studies on the registry are indexed under Anxiety Disorders; 1,390 are open to participants now.

This study's enrollment of 28 is below the median of 80 across 4,174 interventional studies indexed under Anxiety Disorders.

Browse Anxiety Disorders studies →

Lead sponsor

Charite University, Berlin, Germany is the lead sponsor of 836 studies on the registry; 129 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Diagnosis of social anxiety disorder, Performance only subtype due to DSM-5
  • Appropriate abilities to communicate and to complete the questionnaires
  • Written informed consent
  • Possibility of regular attendance at the training sessions
  • Participant is a classical instrumentalist

Exclusion criteria

Exclusion Criteria:

  • Other severe mental conditions than MPA (e.g. schizophrenia, severe depressive episode, addiction)
  • Acute suicidality
  • Epilepsy or other disorders of the central nervous system (e.g. tumor, encephalitis)
  • Contraindications to aerobe exercise Training
  • Start or modification of an anxiolytic pharmacotherapy or other therapy within the last four weeks
  • Current psychotherapy
  • no sufficient capability to consent to trial
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    high-intensive aerobe exercise

    Aerobe bicycle ergometer training within 77-95% of maximum oxygen consumption; duration of each training session: 20 minutes; frequency of training: 6 sessions within 12 days

    Other: high-intensive aerobe exercise

  • Placebo comparator
    low-intensive aerobe exercise

    Aerobe training below 70% of maximum oxygen consumption (including light stretching and simple exercises adapted from yoga figures); duration of training session: 20 minutes; frequency of training: 6 sessions within 12 days

    Other: low-intensive aerobe exercise

Interventions

  • Otherhigh-intensive aerobe exercise

    Aerobe bicycle ergometer training within 77-95% of maximum oxygen consumption; duration of each training session: 20 minutes; frequency of training: 6 sessions within 12 days

  • Otherlow-intensive aerobe exercise

    Aerobe training below 70% of maximum oxygen consumption (including light stretching and simple exercises adapted from yoga figures); duration of training session: 20 minutes; frequency of training: 6 sessions within 12 days

06

What researchers measure

Primary outcomes

  1. Bühnenangstfragebogen

    Bühnenangstfragebogen is a questionnaire measuring Music Performance Anxiety. It is the German Version of the PAQ (Performance Anxiety Questionnaire)

    Time frame: Change from Baseline to post therapy (+12 days) and from Baseline to follow-up (+22 days)

Secondary outcomes

  1. Screening für somatoforme Störungen (SOMS-7T)

    SOMS-7T is a questionnaire for detecting the changes in somatisation

    Time frame: Change from Baseline to post therapy (+12 days) and from Baseline to follow-up (+22 days)

  2. Screening für somatoforme Störungen (SOMS-2)

    SOMS-2 is a questionnaire for detecting the severity of somatisation

    Time frame: Only one assessment at baseline to assess differences between the two intervention groups

  3. NEO-FFI personality inventory

    personality inventory measuring neuroticism, extraversion, openness to experience, agreeableness, conscientiousness

    Time frame: Only one assessment at baseline to assess differences between the two intervention groups

  4. Resilienzskala (RS-13)

    A Questionnaire measuring resilience

    Time frame: Change from Baseline to post therapy (+12 days) and from Baseline to follow-up (+22 days)

  5. Trierer Inventar zum chronischen Stress (TICS)

    TICS is an inventory measuring chronic stress

    Time frame: Only one assessment at baseline to assess differences between the two intervention groups

  6. Angstkontrollfragebogen (AKF)

    AKF is the German Version of the Anxiety Control Questionnaire

    Time frame: Change from Baseline to post therapy (+12 days) and from Baseline to follow-up (+22 days)

  7. Anxiety Sensitivity Index (ASI)

    ASI is a Questionnaire measuring anxiety sensitivity

    Time frame: Change from Baseline to post therapy (+12 days) and from Baseline to follow-up (+22 days)

  8. Beck Anxiety Inventory (BAI)

    BAI is a questionnaire measuring anxiety

    Time frame: Change from Baseline to post therapy (+12 days) and from Baseline to follow-up (+22 days)

  9. Beck Depression Inventory (BDI)

    BDI is a questionnaire measuring depression

    Time frame: Change from Baseline to post therapy (+12 days) and from Baseline to follow-up (+22 days)

  10. Liebowitz Social Anxiety Scale (LSAS)

    LSAS is a questionnaire measuring social anxiety

    Time frame: Change from Baseline to post therapy (+12 days) and from Baseline to follow-up (+22 days)

  11. Fragebogen zu sozialphobischen Kognitionen (SPK)

    SPK is the German Version of the social cognitions questionnaire. It measures cognitions in social situations

    Time frame: Change from Baseline to post therapy (+12 days) and from Baseline to follow-up (+22 days)

  12. saliva cortisol hormone

    Cortisol is an established marker of the psychophysiological stress response and obtained with help of Salivettes absorbing saliva

    Time frame: Change from Baseline to post therapy (+12 days) and in performance situations 1 and 2 (+15 days)

  13. saliva alpha Amylase hormone

    Alpha amylase is an established marker of the psychophysiological stress Response and obtained with help of Salivettes absorbing saliva

    Time frame: From Baseline to post therapy (+12 days) and during performance situations 1 (Baseline) and 2 (+15 days)

  14. heart rate

    Measurement of heart rate

    Time frame: Change from Baseline to post therapy (+12 days), from Baseline to Follow-up and during performance situations 1 (Baseline) and 2 (+15 days)

  15. heart rate variability

    heart rate variability is a non-invasive method to measure autonomic nervous System function

    Time frame: Change from Baseline to post therapy (+12 days), from Baseline to follow-up (+22 days) and during performance situations 1 (Baseline) and 2 (+15 days)

  16. visual analogue scale for anxiety (VAS)

    VAS is a scale measuring an individual's anxiety in a specific situation

    Time frame: Change during performance situations 1 (baseline) and 2 (+15 days)

  17. Accelerometer

    With help of an accelerometer the activity level of a person can be measured

    Time frame: Change from Baseline to post therapy (+12 days) and from Baseline to follow-up (+22 days)

  18. International Physical Activity Questionnaire (IPAQ-SF)

    With the IPAQ-SF the physical activity of an individual during the last 7 days can be measured

    Time frame: Change from Baseline to post therapy (+12 days) and from Baseline to follow-up (+22 days)

  19. K-MPAI

    Kenny Music Performance Anxiety Inventory is a questionnaire measuring Music Performance Anxiety

    Time frame: Change from Baseline to post therapy (+12 days) and from Baseline to follow-up (+22 days)

07

Study locations

1 site
  • Department of Psychiatry and Psychotherapy, Charité - Universitätsmedizin Berlin, Campus Mitte
    Berlin, 10117, Germany
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 15, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03562312
Lead sponsor
Charite University, Berlin, Germany
Collaborators
Friede Springer Stiftung, Germany
Responsible party
Dr. Jens Plag (MD, Charite University, Berlin, Germany) — Principal investigator
First posted
Jun 19, 2018
Start date
May 3, 2018
Primary completion
Apr 14, 2020
Completion
Apr 14, 2020
Last update
Apr 15, 2020

Study contacts

Alexander Schmidt
study chair · Charite University, Berlin, Germany

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion